Delta and epsilon crystal forms of Imatinib mesylate

Details Delta and epsilon crystal forms of Imatinib mesylate Delta and epsilon crystal forms of Imatinib mesylate

2011-02-01

2011-02-01

Marschel, Ardin (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S252010, C514S272000, C544S295000, C544S322000, C544S331000, C544S332000

Reexamination Certificate

active

07879860

ABSTRACT:
The invention relates to the delta and epsilon crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2 -ylamino)phenyl]-benzamide (the compound of formula I, see below), certain processes for their preparation, pharmaceutical compositions containing these crystal forms, and their use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, and their use as an intermediate or for the preparation of pharmaceutical preparations for use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, especially humans.

REFERENCES:
patent: 5521184 (1996-05-01), Zimmermann
patent: 99/03854 (1999-01-01), None
patent: 2004/106326 (2004-12-01), None
patent: 2005/077933 (2005-08-01), None
patent: 2005/095379 (2005-10-01), None
patent: 2006/024863 (2006-03-01), None
patent: 2006/048890 (2006-05-01), None
patent: 2006/054314 (2006-05-01), None
Ansel et al. pp. 89-91, pp. 186-187, Pharmaceutical Dosage forms and Drug delivery systems, 7th edition, Copyright 1999.
Morissette et al. Advanced Drug Delivery Reviews 2004, 56, 275-300.
Hernandez-Boluda et al., “Imatinib Mesylate (GLEEVEC®/GLIVEC®): A New Therapy for Chronic Mueloid Leukemia and Other Malignancies”, Drugs of today, 2002, vol. 38 (9), pp. 601-613.
Reichardt P. et al., “Molecular response of gastrointestinal stromal tumor after treatment with tyrosine kinase inhibitor imatinib mesylate”, J Clin, Pathol., 2004, vol. 57, pp. 215-217.
Daniels, Craig E. et al., “Imatinib mesylate inhibits the profibrogenic activity of Tgf-β and prevents bleomycin-mediated lung fibrosis”, J. Clin. Invest., 2004, vol. 114(9), pp. 1308-1316.

Affiliated with

Also associated with

Rating

Delta and epsilon crystal forms of Imatinib mesylate does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Delta and epsilon crystal forms of Imatinib mesylate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Delta and epsilon crystal forms of Imatinib mesylate will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2633863